Want to see HK:6086 full AI Analyst Report?
Fangzhou Inc. (6086) AI Stock Analysis
Fangzhou Inc.
(HKEX:6086)
The score is driven by improving financial performance (return to profitability and positive free cash flow), supported by positive near-term technical momentum. These positives are tempered by very expensive valuation (high P/E) and technically overbought signals that raise downside risk, while margins remain thin and the turnaround is still fragile.
Fangzhou Inc. (6086) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 1.39B
- Dividend Yield
- ―
- Average Volume (3M)
- 284.86K
- Price to Earnings (P/E)
- 141.4
- Beta (1Y)
- 1.87
- Revenue Growth
- 38.59%
- EPS Growth
- ―
- Country
- Hong Kong
- Employees
- 494
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Pharmaceuticals
Fangzhou Inc. Business Overview & Revenue Model
Company Description
Headquartered in Guangzhou, China, Fangzhou Inc. delivers comprehensive online chronic disease management services throughout the nation. The company leverages its dedicated digital platform to assist individuals grappling with long-term health issue...
Fangzhou Inc. Financial Statement Overview
Summary
2025 annual results show a clear improvement: revenue grew ~19%, the company returned to positive operating profit and net income, and operating/free cash flow turned solidly positive. Offsetting this, profitability remains fragile (net margin ~0.3% and low operating margin), gross margin has trended down versus 2022–2024, and prior-year losses/balance-sheet volatility suggest the turnaround is not yet fully proven.
Income Statement
56NeutralBalance Sheet
62PositiveCash Flow
68Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.86B | 3.53B | 2.71B | 2.43B | 2.20B | 1.76B |
| Gross Profit | 559.94M | 559.44M | 515.94M | 487.41M | 441.20M | 262.74M |
| EBITDA | 20.18M | 33.60M | -719.97M | -174.76M | -109.41M | -210.41M |
| Net Income | 8.26M | 11.83M | -854.88M | -196.79M | -383.30M | -303.96M |
Balance Sheet | ||||||
| Total Assets | 973.13M | 814.24M | 664.09M | 521.37M | 582.57M | 426.54M |
| Cash, Cash Equivalents and Short-Term Investments | 505.18M | 377.52M | 261.51M | 146.32M | 134.91M | 84.66M |
| Total Debt | 22.88M | 35.81M | 50.89M | 49.72M | 1.99B | 18.27M |
| Total Liabilities | 676.72M | 660.44M | 532.39M | 2.42B | 2.50B | 2.07B |
| Stockholders Equity | 296.21M | 153.79M | 131.70M | -1.90B | -1.92B | -1.34B |
Cash Flow | ||||||
| Free Cash Flow | 53.25M | 65.40M | 15.63M | 16.63M | -65.42M | -262.72M |
| Operating Cash Flow | 58.25M | 70.86M | 19.54M | 22.28M | -59.28M | -246.43M |
| Investing Cash Flow | 9.43M | 1.52M | -111.51M | 16.42M | 14.31M | -4.32M |
| Financing Cash Flow | 113.13M | -16.96M | 119.62M | -29.31M | 82.23M | -11.41M |
Fangzhou Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6086, the sentiment is Positive. The current price of 1.00 is above the 20-day moving average (MA) of 0.89, above the 50-day MA of 0.80, and below the 200-day MA of 1.29, indicating a neutral trend. The MACD of 0.05 indicates Negative momentum. The RSI at 72.89 is Negative, neither overbought nor oversold. The STOCH value of 74.92 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:6086.
Fangzhou Inc. Peers Comparison
Overall Rating
- HK:608659Neutral
HK:988656Neutral
HK:256348Neutral
HK:122846Neutral
HK:164342Neutral
HK:289842Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:6086 | 59Neutral | HKD 1.39B | 141.42 | 3.67% | ― | 38.59% | ― |
| HK:9886 | 56Neutral | HKD 1.10B | -15.52 | -3.87% | ― | 8.73% | 80.38% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:2563 | 48Neutral | HKD 1.32B | -9.90 | -16.60% | ― | ― | ― |
| HK:1228 | 46Neutral | HKD 1.06B | -9.52 | 30.32% | ― | -8.00% | 51.26% |
| HK:1643 | 42Neutral | HKD 237.60M | -4.64 | -8.62% | ― | 2.06% | -298.25% |
| HK:2898 | 42Neutral | HKD 970.43M | -8.74 | -39.21% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:6086 | Fangzhou Inc. | 1.00 | -2.62 | -72.38% | |
| HK:9886 | Dingdang Health Technology Group Ltd. | 0.90 | -0.19 | -17.43% | |
| HK:1228 | CANbridge Pharmaceuticals Inc. | 1.77 | -0.21 | -10.61% | |
| HK:1643 | Modern Chinese Medicine Group Co. Ltd. | 0.33 | -0.38 | -53.52% | |
| HK:2898 | Sunho Biologics,Inc. | 6.39 | -1.61 | -20.13% | |
| HK:2563 | Beijing Biostar Pharmaceuticals Co., Ltd. Class H | 3.40 | 0.22 | 6.92% |
Fangzhou Inc. Corporate Events
Fangzhou Inc. Launches New Share Incentive Scheme Funded by Existing Stock
Fangzhou Inc. has adopted a new decade-long share incentive scheme funded entirely by existing shares, avoiding any issuance of new equity and therefore not requiring shareholder approval under Hong Kong listing rules. The plan targets employees, rel...
Fangzhou boosts AI investment as interim revenue and user base surge
Fangzhou reported strong interim results for the first half of 2026, underpinned by accelerated investment in its proprietary XingShi large language model to enhance AI-driven solutions across clinical data management, decision support, and operation...
Fangzhou Inc. Sets Board Meeting to Approve Interim Results and Consider Dividend
Fangzhou Inc., a Cayman Islands-incorporated company listed in Hong Kong under stock code 6086, is overseen by a board that includes executive, non-executive and independent non-executive directors, reflecting a governance framework aligned with Hong...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 29, 2026